• OPEN AN ACCOUNT
Indian Indices
Sensex
77,728.16 -281.09
( -0.36%)
Global Indices
Nasdaq
53,757.60 -103.39
(-0.19%)
Dow Jones
7,807.18 -12.81
(-0.16%)
Hang Seng
69,148.70 434.90
(0.63%)
Nikkei 225
10,727.81 -22.30
(-0.21%)
Forex
USD-INR
95.39 0.02
(0.02%)
EUR-INR
109.98 -0.03
(-0.03%)
GBP-INR
128.68 -0.13
(-0.10%)
JPY-INR
0.60 0.00
(-0.03%)

EQUITY - MARKET SCREENER

Cipla Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500087
INE059A01026
423.3581313
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CIPLA
35.72
117138.71
EPS(TTM)
Face Value()
Div & Yield %
40.59
2
0.9
 

cipla ltd
InvaGen receives EIR report for its facility in Hauppauge, New York
Aug 04,2026
Cipla announced that its wholly owned subsidiary, InvaGen Pharmaceuticals (InvaGen) has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection of its manufacturing facility located at Hauppauge, Long Island, New York, USA.